GLP ‐1 Receptor Agonists and Substance Use Disorders in Older Adults With Type 2 Diabetes: A Target Trial Emulation
Main finding · SUD hospitalizationResult — go to the resultHazard ratio 0.76 95% CI 0.67–0.86Authors' conclusion
Among older adults with T2D, GLP-1RA use was associated with reduced SUD-related hospitalization versus DPP4i use
Study context
- Population
- Older adults (aged ≥65) with coexisting T2D and substance use disorders, Medicare data 2016–2020matched cohorts
- Exposure
- GLP-1 RA initiators vs new users of DPP-4i or SGLT2i
- Outcome
- Hospitalization for any substance use disorders (SUD)
Methodological detailstarget trial emulation, propensity score 1:1 matching, active comparator new-user
- Target trial emulation
- Propensity score 1:1 matching
- Active comparator new-user
Main finding
SUD hospitalization
Hazard ratio
0.76
95% CI 0.67–0.86
GLP-1RAvs DPP4i
HR 0.76 (95% CI 0.67–0.86)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| OUD hospitalization, GLP-1RAvs DPP4i | 0.64 (0.43–0.96) | |
| AUD hospitalization, GLP-1RAvs DPP4iNonsignificant trend | 0.76 (0.53–1.08) | |
| 0.512Hazard ratio (log scale) |
Original publication
GLP ‐1 Receptor Agonists and Substance Use Disorders in Older Adults With Type 2 Diabetes: A Target Trial Emulation. Obesity (Silver Spring). Published 15 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →